Strategies to manage hepatitis C virus (HCV) disease burden

Heiner Wedemeyer; Ann Sofi Duberg; Maria Asuncion Buti; William M C Rosenberg; Sona Frankova; Gamal Esmat; Necati Ormeci; H Van Vlierberghe; Michael Gschwantler; Ulus Salih Akarca; Soo Aleman; Ismail Balik; T Berg; Florian K Bihl; M Bilodeau; A J Blasco; Carlos Eduardo Brandao-Mello; Philip Bruggmann; Filipe Calinas; J L Calleja; Hugo Cheinquer; P B Christensen; M Clausen; H S M Coelho; Markus Cornberg; Matthew E Cramp; Gregory J Dore; Wahid H Doss; Mohammed H El-Sayed; Gul Ergor; Chris Estes; K Falconer; J Felix; M L G Ferraz; P R Ferreira; Javier Garcia-Samaniego; J Gerstoft; Jose A Giria; Fernando Lopes Goncales; M Guimaraes Pessoa; Christophe Hezode; S J Hindman; H Hofer; P Husa; Ramazan Idilman; M Kaberg; Kelly Kaita; Achim Kautz; Sabahattin Kaymakoglu; Mel Krajden; H Krarup; Wim J Laleman; D Lavanchy; P Lazaro; R T Marinho; P Marotta; Stefan Mauss; Maria Cassia Jacintho Mendes-Correa; Christophe A Moreno; B Mullhaupt; Robert P Myers; V Nemecek; Anne Lindebo Holm Ovrehus; J Parkes; Kevork Minas Peltekian; Alnoor S Ramji; Homie A Razavi; N Reis; Stuart Keith Roberts; Francoise Roudot-Thoraval; Stephen D Ryder; Rui Sarmento-Castro; Christoph M Sarrazin; David Semela; M Sherman; Gamal Elsayed Shiha; J Sperl; Peter Starkel; R E Stauber; Alexander James V Thompson; P Urbanek; P Van Damme; I Van Thiel; Dominique M Vandijck; W Vogel; Imam A Waked; N Weis; Johannes Wiegand; Ayman Yosry; Amany Zekry; Francesco Negro; William Sievert; Erin E Gower

doi:10.1111/jvh.12249

Strategies to manage hepatitis C virus (HCV) disease burden

Heiner Wedemeyer, Ann Sofi Duberg, Maria Asuncion Buti, William M C Rosenberg, Sona Frankova, Gamal Esmat, Necati Ormeci, H Van Vlierberghe, Michael Gschwantler, Ulus Salih Akarca, Soo Aleman, Ismail Balik, T Berg, Florian K Bihl, M Bilodeau, A J Blasco, Carlos Eduardo Brandao-Mello, Philip Bruggmann, Filipe Calinas, J L CallejaHugo Cheinquer, P B Christensen, M Clausen, H S M Coelho, Markus Cornberg, Matthew E Cramp, Gregory J Dore, Wahid H Doss, Mohammed H El-Sayed, Gul Ergor, Chris Estes, K Falconer, J Felix, M L G Ferraz, P R Ferreira, Javier Garcia-Samaniego, J Gerstoft, Jose A Giria, Fernando Lopes Goncales, M Guimaraes Pessoa, Christophe Hezode, S J Hindman, H Hofer, P Husa, Ramazan Idilman, M Kaberg, Kelly Kaita, Achim Kautz, Sabahattin Kaymakoglu, Mel Krajden, H Krarup, Wim J Laleman, D Lavanchy, P Lazaro, R T Marinho, P Marotta, Stefan Mauss, Maria Cassia Jacintho Mendes-Correa, Christophe A Moreno, B Mullhaupt, Robert P Myers, V Nemecek, Anne Lindebo Holm Ovrehus, J Parkes, Kevork Minas Peltekian, Alnoor S Ramji, Homie A Razavi, N Reis, Stuart Keith Roberts, Francoise Roudot-Thoraval, Stephen D Ryder, Rui Sarmento-Castro, Christoph M Sarrazin, David Semela, M Sherman, Gamal Elsayed Shiha, J Sperl, Peter Starkel, R E Stauber, Alexander James V Thompson, P Urbanek, P Van Damme, I Van Thiel, Dominique M Vandijck, W Vogel, Imam A Waked, N Weis, Johannes Wiegand, Ayman Yosry, Amany Zekry, Francesco Negro, William Sievert, Erin E Gower

Research output: Contribution to journal › Article › Research › peer-review

183 Citations (Scopus)

Abstract

The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10 , this analysis suggests it is possible to achieve elimination of HCV (defined as a >90 decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

Original language	English
Pages (from-to)	60 - 89
Number of pages	30
Journal	Journal of Viral Hepatitis
Volume	21
Issue number	Supplement S1
DOIs	https://doi.org/10.1111/jvh.12249
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/jvh.12249

Cite this

Wedemeyer, H., Duberg, A. S., Buti, M. A., Rosenberg, W. M. C., Frankova, S., Esmat, G., Ormeci, N., Van Vlierberghe, H., Gschwantler, M., Akarca, U. S., Aleman, S., Balik, I., Berg, T., Bihl, F. K., Bilodeau, M., Blasco, A. J., Brandao-Mello, C. E., Bruggmann, P., Calinas, F., ... Gower, E. E. (2014). Strategies to manage hepatitis C virus (HCV) disease burden. Journal of Viral Hepatitis, 21(Supplement S1), 60 - 89. https://doi.org/10.1111/jvh.12249

@article{9d41e31d36a24e928e6de5c75d0aa37a,

title = "Strategies to manage hepatitis C virus (HCV) disease burden",

abstract = "The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10 , this analysis suggests it is possible to achieve elimination of HCV (defined as a >90 decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.",

author = "Heiner Wedemeyer and Duberg, {Ann Sofi} and Buti, {Maria Asuncion} and Rosenberg, {William M C} and Sona Frankova and Gamal Esmat and Necati Ormeci and {Van Vlierberghe}, H and Michael Gschwantler and Akarca, {Ulus Salih} and Soo Aleman and Ismail Balik and T Berg and Bihl, {Florian K} and M Bilodeau and Blasco, {A J} and Brandao-Mello, {Carlos Eduardo} and Philip Bruggmann and Filipe Calinas and Calleja, {J L} and Hugo Cheinquer and Christensen, {P B} and M Clausen and Coelho, {H S M} and Markus Cornberg and Cramp, {Matthew E} and Dore, {Gregory J} and Doss, {Wahid H} and El-Sayed, {Mohammed H} and Gul Ergor and Chris Estes and K Falconer and J Felix and Ferraz, {M L G} and Ferreira, {P R} and Javier Garcia-Samaniego and J Gerstoft and Giria, {Jose A} and Goncales, {Fernando Lopes} and {Guimaraes Pessoa}, M and Christophe Hezode and Hindman, {S J} and H Hofer and P Husa and Ramazan Idilman and M Kaberg and Kelly Kaita and Achim Kautz and Sabahattin Kaymakoglu and Mel Krajden and H Krarup and Laleman, {Wim J} and D Lavanchy and P Lazaro and Marinho, {R T} and P Marotta and Stefan Mauss and Mendes-Correa, {Maria Cassia Jacintho} and Moreno, {Christophe A} and B Mullhaupt and Myers, {Robert P} and V Nemecek and Ovrehus, {Anne Lindebo Holm} and J Parkes and Peltekian, {Kevork Minas} and Ramji, {Alnoor S} and Razavi, {Homie A} and N Reis and Roberts, {Stuart Keith} and Francoise Roudot-Thoraval and Ryder, {Stephen D} and Rui Sarmento-Castro and Sarrazin, {Christoph M} and David Semela and M Sherman and Shiha, {Gamal Elsayed} and J Sperl and Peter Starkel and Stauber, {R E} and Thompson, {Alexander James V} and P Urbanek and {Van Damme}, P and {Van Thiel}, I and Vandijck, {Dominique M} and W Vogel and Waked, {Imam A} and N Weis and Johannes Wiegand and Ayman Yosry and Amany Zekry and Francesco Negro and William Sievert and Gower, {Erin E}",

year = "2014",

doi = "10.1111/jvh.12249",

language = "English",

volume = "21",

pages = "60 -- 89",

journal = "Journal of Viral Hepatitis",

issn = "1352-0504",

publisher = "Wiley-Blackwell",

number = "Supplement S1",

}

Wedemeyer, H, Duberg, AS, Buti, MA, Rosenberg, WMC, Frankova, S, Esmat, G, Ormeci, N, Van Vlierberghe, H, Gschwantler, M, Akarca, US, Aleman, S, Balik, I, Berg, T, Bihl, FK, Bilodeau, M, Blasco, AJ, Brandao-Mello, CE, Bruggmann, P, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, WH, El-Sayed, MH, Ergor, G, Estes, C, Falconer, K, Felix, J, Ferraz, MLG, Ferreira, PR, Garcia-Samaniego, J, Gerstoft, J, Giria, JA, Goncales, FL, Guimaraes Pessoa, M, Hezode, C, Hindman, SJ, Hofer, H, Husa, P, Idilman, R, Kaberg, M, Kaita, K, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, WJ, Lavanchy, D, Lazaro, P, Marinho, RT, Marotta, P, Mauss, S, Mendes-Correa, MCJ, Moreno, CA, Mullhaupt, B, Myers, RP, Nemecek, V, Ovrehus, ALH, Parkes, J, Peltekian, KM, Ramji, AS, Razavi, HA, Reis, N, Roberts, SK, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Sarrazin, CM, Semela, D, Sherman, M, Shiha, GE, Sperl, J, Starkel, P, Stauber, RE, Thompson, AJV, Urbanek, P, Van Damme, P, Van Thiel, I, Vandijck, DM, Vogel, W, Waked, IA, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Negro, F, Sievert, W & Gower, EE 2014, 'Strategies to manage hepatitis C virus (HCV) disease burden', Journal of Viral Hepatitis, vol. 21, no. Supplement S1, pp. 60 - 89. https://doi.org/10.1111/jvh.12249

TY - JOUR

T1 - Strategies to manage hepatitis C virus (HCV) disease burden

AU - Wedemeyer, Heiner

AU - Duberg, Ann Sofi

AU - Buti, Maria Asuncion

AU - Rosenberg, William M C

AU - Frankova, Sona

AU - Esmat, Gamal

AU - Ormeci, Necati

AU - Van Vlierberghe, H

AU - Gschwantler, Michael

AU - Akarca, Ulus Salih

AU - Aleman, Soo

AU - Balik, Ismail

AU - Berg, T

AU - Bihl, Florian K

AU - Bilodeau, M

AU - Blasco, A J

AU - Brandao-Mello, Carlos Eduardo

AU - Bruggmann, Philip

AU - Calinas, Filipe

AU - Calleja, J L

AU - Cheinquer, Hugo

AU - Christensen, P B

AU - Clausen, M

AU - Coelho, H S M

AU - Cornberg, Markus

AU - Cramp, Matthew E

AU - Dore, Gregory J

AU - Doss, Wahid H

AU - El-Sayed, Mohammed H

AU - Ergor, Gul

AU - Estes, Chris

AU - Falconer, K

AU - Felix, J

AU - Ferraz, M L G

AU - Ferreira, P R

AU - Garcia-Samaniego, Javier

AU - Gerstoft, J

AU - Giria, Jose A

AU - Goncales, Fernando Lopes

AU - Guimaraes Pessoa, M

AU - Hezode, Christophe

AU - Hindman, S J

AU - Hofer, H

AU - Husa, P

AU - Idilman, Ramazan

AU - Kaberg, M

AU - Kaita, Kelly

AU - Kautz, Achim

AU - Kaymakoglu, Sabahattin

AU - Krajden, Mel

AU - Krarup, H

AU - Laleman, Wim J

AU - Lavanchy, D

AU - Lazaro, P

AU - Marinho, R T

AU - Marotta, P

AU - Mauss, Stefan

AU - Mendes-Correa, Maria Cassia Jacintho

AU - Moreno, Christophe A

AU - Mullhaupt, B

AU - Myers, Robert P

AU - Nemecek, V

AU - Ovrehus, Anne Lindebo Holm

AU - Parkes, J

AU - Peltekian, Kevork Minas

AU - Ramji, Alnoor S

AU - Razavi, Homie A

AU - Reis, N

AU - Roberts, Stuart Keith

AU - Roudot-Thoraval, Francoise

AU - Ryder, Stephen D

AU - Sarmento-Castro, Rui

AU - Sarrazin, Christoph M

AU - Semela, David

AU - Sherman, M

AU - Shiha, Gamal Elsayed

AU - Sperl, J

AU - Starkel, Peter

AU - Stauber, R E

AU - Thompson, Alexander James V

AU - Urbanek, P

AU - Van Damme, P

AU - Van Thiel, I

AU - Vandijck, Dominique M

AU - Vogel, W

AU - Waked, Imam A

AU - Weis, N

AU - Wiegand, Johannes

AU - Yosry, Ayman

AU - Zekry, Amany

AU - Negro, Francesco

AU - Sievert, William

AU - Gower, Erin E

PY - 2014

Y1 - 2014

N2 - The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10 , this analysis suggests it is possible to achieve elimination of HCV (defined as a >90 decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

AB - The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10 , this analysis suggests it is possible to achieve elimination of HCV (defined as a >90 decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

UR - http://onlinelibrary.wiley.com/doi/10.1111/jvh.12249/pdf

U2 - 10.1111/jvh.12249

DO - 10.1111/jvh.12249

M3 - Article

SN - 1352-0504

VL - 21

SP - 60

EP - 89

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

IS - Supplement S1

ER -

Strategies to manage hepatitis C virus (HCV) disease burden

Abstract

UN SDGs

Access to Document

Other files and links

Cite this